 The independent Data Safety Monitoring Board DSMB has reviewed safety data for the fully enrolled first cohort of ten patients of the Phase 12 trial evaluating UniQure NVs NASDAQ: QURE AMT-130 for Huntingtons disease. The DSMB recommended continued dosing in the study. 